Clinical trials: SLE Nephritis
Nephritis, Lupus
Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
lupus nephritis accounts for the most morbidity and mortality in patients with SLE. Glucocorticoids combined with cyclophosphamide (CYC) are effective for the treatment of patients with proliferative lupus nephritis and have been…
- Trial name
- NCT00268567
- Testing
- leflunomide combined with prednisone
- Where
- 8 sites in China
- Sponsor
- Peking University
Lupus Nephritis
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.
The purpose of the study is to determine whether mycophenolate mofetil is superior to azathioprine to prevent flares of lupus nephritis.
- Trial name
- MAINTAIN (NCT00204022)
- Testing
- Mycophenolate mofetil, Azathioprine
- Where
- Belgium
- Volunteers
- 105 people
- Sponsor
- Frédéric A. Houssiau, MD, PhD
Lupus Nephritis
Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children
The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory/recurrent lupus nephritis.
- Trial name
- CAR-T (NCT06904729)
- Testing
- Low-dose CAR-T cells group, High-dose CAR-T cells group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE)
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory autoimmune disease, however not all disease responds or remains in response to CD19 targeted CAR-T cells.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE), Dermatomyositis (DM), Systemic Sclerosis (SSc)
- Trial name
- NCT07729995
- Testing
- LMY-922
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Luminary Therapeutics
Lupus Nephritis, Systemic Lupus Erythematosus
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory…
- Conditions
- Lupus Nephritis, Systemic Lupus Erythematosus, SLE - Systemic Lupus Erythematosus, Lupus Nephritis - WHO Class III
- Trial name
- RECLAIM-LN (NCT07570862)
- Testing
- FT819
- Where
- 12 sites in United States
- Volunteers
- 53 people
- Sponsor
- Fate Therapeutics
Lupus Nephritis
Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis
To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis.
- Trial name
- NCT01042457
- Testing
- Mycophenolate mofetil
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- Chulalongkorn University
Lupus Nephritis
The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis
To investigate the efficacy and safety of enteric-coated mycophenolate sodium (Myfortic) as compared to intravenous cyclophosphamide in the treatment of active nephritis.
- Trial name
- CONTROL (NCT01015456)
- Testing
- mycophenolate sodium, cyclophosphamide
- Where
- 3 sites in Thailand
- Volunteers
- 59 people
- Sponsor
- Chulalongkorn University
IgA Nephropathy, Lupus Nephritis (LN)
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy…
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Trial name
- NCT06419205
- Testing
- ADX-097
- Where
- 4 sites in United States, Brazil
- Volunteers
- 30 people
- Sponsor
- Akebia Therapeutics
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
This was a prospective open label randomized control trial, which was conducted for a period of one and half year from January 2014 to June 2015.
- Trial name
- NCT03200002
- Testing
- Cyclophosphamide, Mycophenolate Mofetil
- Volunteers
- 49 people
- Sponsor
- Chitwan Medical College
Renal Insufficiency, Infection
Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children
Proliferative lupus nephritis (LN)is the predominant cause of morbidity and mortality in juvenile Systemic Lupus Erythematosus (SLE).
- Trial name
- Low/highIVCY (NCT01861561)
- Testing
- Low-dose intravenous cyclophosphamide, High-dose intravenous cyclophosphamide
- Where
- Thailand
- Volunteers
- 43 people
- Sponsor
- Mahidol University
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Systemic Lupus Erythematosus, Lupus Nephritis
Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis
The treatment of the multisystem autoimmune disease systemic lupus erythematosus (SLE) remains a challenge, particularly when there is renal involvement (lupus nephritis).
- Trial name
- RITUXILUP (NCT01773616)
- Testing
- Oral prednisolone, Rituximab, Mycophenolate mofetil
- Where
- 11 sites in United Kingdom
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Systemic Lupus Erythematosus Nephritis
Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis
This is a 5-year project, involving 185 partners from 46 countries (110 in 21 EU States and 75 in 25 extra-EU States), with a randomised clinical trials (RCT) in juvenile systemic lupus erythematosus (JSLE): 5-year phase III…
- Trial name
- NCT00336414
- Testing
- cyclophosphamide-prednisone-azathioprine
- Where
- Italy
- Sponsor
- Istituto Giannina Gaslini
Atherosclerosis, Lupus Nephritis
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma.
- Trial name
- NCT03526042
- Testing
- Losartan, Enalapril
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Lupus Nephritis, SLE Nephritis
The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis
Pediatric Lupus nephritis which is a sever and common complication to childhood onset systemic lupus erythematous is an aggressive inflammatory process triggered by the deposition of antigen-antibody complex in kidney tissue.
- Trial name
- NCT05714670
- Testing
- Curcumin Oral Capsule
- Where
- Egypt
- Volunteers
- 72 people
- Sponsor
- Ain Shams University
Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in…
- Conditions
- Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- Trial name
- NCT07729826
- Testing
- C-CAR168
- Volunteers
- 50 people
- Sponsor
- AbelZeta Inc.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single…
- Trial name
- NCT07328581
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Autoimmune Diseases, Systemic Lupus Erthematosus (SLE)
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
This is an exploratory, open-label, single-arm Phase 1 clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of QT-219C.
- Conditions
- Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome, IgA Nephropathy (IgAN)
- Trial name
- NCT07507201
- Testing
- UCAR T-cell
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Lupus Nephritis
A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital
systemic lupus erthrematosus is an inflamatory and autoimmune condition characterized by multisystem affection and chronic course with unpredictable flares despite potentially afffecting every oragan .
- Trial name
- NCT06491602
- Testing
- renal biobsy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Sohag University
Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Childhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement.
- Trial name
- LIGHT (NCT07719140)
- Testing
- High-dose prednisone, Low-dose prednisone
- Where
- 8 sites in China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital